Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5316945 | 0.89 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL3825769 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL8985764 | 0.82 | ALDH1A1 (0.55) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL5987538 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL3081344 | 0.82 | ALDH1A1 (0.51) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL10356325 | 0.82 | ALDH1A1 (0.56) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL7978087 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL31096462 | 0.81 | ALDH1A1 (0.54) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL536014 | 0.81 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2GAAMAPK1 | |
| SCHEMBL2975924 | 0.81 | ALDH1A1 (0.58) | ALDH1A1KDM4ESMN1; SMN2MAPK1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | OSI PHARMACEUTICALS, INC. | 2003-01-09 | — | — | US | disclosed |
| EP-0779887-B1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODIESTERASE INHIBITING ACTIVITY | OTSUKA PHARMA CO LTD (JP) | 2001-05-23 | — | — | EP | disclosed |
| US-5998437-A | ARTERIOSCLEROSIS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1999-12-07 | — | — | US | disclosed |
| EP-0779887-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-06-25 | — | — | EP | disclosed |
| WO-1997003070-A1 | NOVEL BENZIMIDAZOLE DERIVATIVES HAVING CGMP-PHOSPHODISTERASE INHIBITING ACTIVITY | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030008832-A1 | Method of inhibiting neoplastic cells with benzimidazole derivatives | MKI67, CCNI, TMBIM6 | ALDH1A1 487/4885KDM4E 2132/4885SMN1; SMN2 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.